Dynavax (DVAX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM ESTFourth quarter 2018 HEPLISAV-B® net product revenue of $3.9 millionPhase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual MeetingSD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapyConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT
BERKELEY, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2018. Â
I am proud of our 2018 achievements,... More
